Welcome to our dedicated page for Lantheus Holdings news (Ticker: LNTH), a resource for investors and traders seeking the latest updates and insights on Lantheus Holdings stock.
Lantheus Holdings, Inc. reports news on its radiopharmaceutical business, including diagnostic imaging agents, radiotherapeutic assets, regulatory decisions and financial results. The company organizes revenue around Radiopharmaceutical Oncology, Precision Diagnostics and Strategic Partnerships and Other Revenue, with products used by hospitals, independent imaging centers, government facilities and distribution partners in the United States and abroad.
Recurring updates include quarterly earnings, business guidance, FDA activity for products such as PYLARIFY TruVu, PYLARIFY, Lutetium Lu 177 Dotatate (PNT2003) and LNTH-2501, share repurchases, investor presentations and strategic updates involving radiodiagnostics and radiotherapeutic programs.
Lantheus reported a remarkable third quarter for 2022, achieving worldwide revenue of $239.3 million, marking a 134.4% increase year-over-year. The company's GAAP net income surged to $61.2 million or $0.86 per fully diluted share, compared to a loss of $13.4 million in the same quarter of 2021. Adjusted fully diluted EPS was $0.99, up from $0.08 a year earlier. With operating cash flow at $93.6 million and free cash flow of $87.5 million, Lantheus also provided positive guidance for Q4 and updated full-year 2022 expectations.
Lantheus Holdings (NASDAQ: LNTH) announced a conference call and webcast for November 3, 2022, at 8:00 a.m. ET to discuss Q3 2022 financial and operating results. The company encourages participants to register online ahead of time to avoid delays. A replay will be available approximately two hours post-event for 30 days. Lantheus, with over 60 years of experience, focuses on improving patient outcomes through diagnostics and AI solutions in healthcare.
Lantheus Holdings (NASDAQ: LNTH) presented AI data at the 2022 EANM Annual Meeting in Barcelona, showcasing the clinical utility of PYLARIFY AI for prostate cancer treatment. Key highlights include a top-rated presentation demonstrating a strong association between automated PSMA scores and PSA response in prostate cancer, indicating that a quantitative PSMA score can effectively assess treatment response. The company also unveiled new adaptive methodologies improving tumor burden quantification in PSMA PET/CT imaging. PYLARIFY AI is FDA-cleared and aims to enhance diagnostic efficiency.
The Phase III clinical trial of [18F]flurpiridaz PET diagnostic radiopharmaceutical has met its co-primary endpoints for detecting Coronary Artery Disease (CAD), exceeding 60% in both sensitivity and specificity. The trial demonstrated higher efficacy than SPECT Myocardial Perfusion Imaging, with over 600 patients participating across multiple regions. If approved, [18F]flurpiridaz’s longer half-life could significantly increase patient access to PET MPI, enhancing diagnostic accuracy and patient outcomes, as noted by experts at the ASNC Congress.
GE Healthcare and Lantheus Holdings have announced that their Phase III clinical trial of the investigational radiotracer [18F]flurpiridaz has successfully met co-primary endpoints for detecting Coronary Artery Disease (CAD), exceeding 60% in both sensitivity and specificity. This trial demonstrated superior diagnostic efficacy compared to SPECT Myocardial Perfusion Imaging. With a half-life approximately 12 times longer than existing PET tracers, [18F]flurpiridaz could significantly improve patient access to PET MPI if approved.
NORTH BILLERICA, Mass., Sept. 01, 2022 – Lantheus Holdings (NASDAQ: LNTH) announced that Bob Marshall, CFO, and Paul Blanchfield, COO, will present at the Wells Fargo Healthcare Conference on September 8 at 8:00 a.m. ET. The presentation will focus on the company’s commitment to innovative diagnostics and therapeutics, including artificial intelligence solutions that enhance patient outcomes. A live webcast can be accessed through the Investors section of the company's website, with a replay available for 30 days.
Lantheus Holdings reported $223.7 million in worldwide revenue for Q2 2022, marking a 121.4% increase from Q2 2021. The company achieved a GAAP net income of $43.1 million, or $0.61 per diluted share, compared to a net loss of $26.7 million in the previous year. Adjusted fully diluted EPS increased to $0.89 from $0.11. Net cash provided by operating activities was $72.6 million, with free cash flow at $68.3 million. The company has raised its full-year revenue guidance to between $885 million and $905 million.
Lantheus Holdings, Inc. (NASDAQ: LNTH) has announced it will host a conference call and webcast on August 4, 2022, at 8:00 a.m. ET to discuss its second-quarter 2022 financial and operating results. Interested participants should register in advance to avoid delays. A replay will be available shortly after the event and archived for at least 30 days. Lantheus, with over 60 years of experience, focuses on improving patient outcomes through diagnostics, radiotherapeutics, and AI solutions.
Lantheus Holdings has announced key management promotions, with Paul Blanchfield becoming Chief Operating Officer and Dottie Barr promoted to Senior Vice President, Manufacturing and Technical Operations. Effective immediately, these changes aim to leverage their expertise for enhanced strategic execution and patient outcomes. Blanchfield, previously Chief Commercial Officer, is recognized for his role in launching the PSMA PET imaging agent for prostate cancer, while Barr has successfully led manufacturing and supply chain improvements despite pandemic challenges.
Lantheus Holdings presented preliminary results of the PD-L1 Expression in Cancer (PECan) study at the SNMMI Annual Meeting. The study focuses on NM-01, a technetium 99m SPECT/CT imaging agent, which aims to assess PD-L1 expression in cancer cells. Preliminary findings indicate that NM-01 can identify patients likely to respond to checkpoint inhibitor therapies, particularly in non-small cell lung cancer (NSCLC). The study included 10 patients, revealing significant insights into PD-L1 expression and treatment response, suggesting NM-01 could enhance patient selection and monitoring in clinical settings.